BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc. (BEAM) is expected to report earnings on November 3, 2026, before the market open. The consensus earnings estimate is a loss of $1.16 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.1% since its last earnings release on August 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Beam Therapeutics Inc.
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities.
Sector
Healthcare
Industry
Biotechnology